Clinical Research Directory

Inclusion Criteria: * Patient with non-small cell lung cancer (NSCLC), proven by cytology or histology * Patient in clinical stages I-III * Age≥ 18 years * Performance status ≤ 2 at the time of referral to therapy * Patient referred for definitive treatment (e.g. surgery, surgery followed by adjuvant chemotherapy, concomitant radio-chemotherapy, conventional or stereotactic radiotherapy or radiofrequency ablation). * Patient has given his/her written informed consent before any specific procedure from protocol Exclusion Criteria: * Patient, whose disease has progressed within the first 3 months after cancer treatment, e.g. confirmed progressive disease on CT. * Persons deprived of liberty or under guardianship or curators * Dementia, mental alteration, severe psychiatric disease or other circumstances that can compromise informed consent from the patient and/or adherence to the protocol and the monitoring of the trial * Pregnant or breastfeeding women * Patient participating in another interventional study during the surveillance period. This is only relevant for studies that might interfere with the intervention, whereas studies on late effects will not preclude participation in SUPE-R. Participation in protocols related only to initial treatment will not preclude participation in SUPE-R. Cases of doubt will be settled by the steering committee.